Searching for the delta: 5-Aminosalicylic acid therapy for Crohn's disease

Gastroenterology and Hepatology

Volumn 7, Issue 5, 2011, Pages 295-301

  Levesque, Barrett G ^a   Kane, Sunanda V ^a  

^a MAYO CLINIC   (United States)

Author keywords

5 Aminosalicylate; Crohn's disease; Mesalamine; Sulfasalazine

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BUDENOFALK; BUDESONIDE; FOLIC ACID; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE;

ANTICOAGULANT THERAPY; CONGENITAL DISORDER; CORTICOSTEROID THERAPY; CROHN DISEASE; DELAYED DRUG RELEASE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COATING; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; LOW BIRTH WEIGHT; LOW DRUG DOSE; MAINTENANCE THERAPY; NONHUMAN; PREGNANCY; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; SPERMATOZOON MOTILITY; SPONTANEOUS ABORTION; STILLBIRTH; SUSTAINED DRUG RELEASE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 79957965065     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Crohn BB, Ginzburg L, Oppenheimer GD. Landmark article Oct 15, 1932. Regional ileitis. A pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. JAMA. 1984;251:73-79.
2. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161-1168.
3. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254-261.
4. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68:255-266. (Pubitemid 352024383)
5. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250. (Pubitemid 34784976)
6. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319-330. (Pubitemid 43972900)
7. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease - based on results from a regional patient group from the county of Copenhagen. Gut. 1985;26:146-150. (Pubitemid 15105140)
8. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-297.
9. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972;181:555-562.
10. van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980;21:632-635. (Pubitemid 10018354)
11. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17:29-42. (Pubitemid 36140432)
12. Allgayer H, Ahnfelt NO, Kruis W, et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology. 1989;97:38-41. (Pubitemid 19190993)
13. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77(4 pt 2):847-869. (Pubitemid 9242048)
14. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
15. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010;8:CD008870.
16. Feagan BG. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion. Clin Gastroenterol Hepatol. 2004;2:376-378.
17. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983-989.
18. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512. (Pubitemid 39311530)
19. Sipponen T, Nuutinen H, Turunen U, Farkkila M. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis. 2010;16:2131-2136.
20. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249-266. (Pubitemid 14218578)
21. Wright J, Jewell D, Modigliani R, Malchow H. A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease. Inflamm Bowel Dis. 1995;1:241-246.
22. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol. 1987;22:877-883. (Pubitemid 18041645)
23. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993;104:1293-1301. (Pubitemid 23235401)
24. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology. 1994;107:632-633. (Pubitemid 24233348)
25. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol. 1994;19:278-282.
26. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339:370-374. (Pubitemid 28363799)
27. Tromm A, Bunganic I, Tomsova E, et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology. 2011;140:425-434 e421; quiz e413-e424.
28. Mahmud N, Kamm MA, Dupas JL, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut. 2001;49:552-556. (Pubitemid 32896987)
29. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther. 1990;4:55-64.
30. Thomson AB, Wright JP, Vatn M, et al. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther. 1995;9:673-683. (Pubitemid 26042105)
31. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology. 1997;112:1069-1077. (Pubitemid 27157516)
32. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology. 1993;104:435-439.
33. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2005;1:CD003715.
34. Arber N, Odes HS, Fireman Z, et al. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol. 1995;20:203-206.
35. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet. 1980;1:514.
36. Ford AC, Khan KJ, Talley NJ, Moayyedi P. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol. 2010;106:413-420.
37. Gordon M, Naidoo K, Thomas AG, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2011;1:CD008414.
38. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956-963. (Pubitemid 20338451)
39. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther. 1994;8:35-43.
40. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology. 2004;127:730-740. (Pubitemid 39208406)
41. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127:723-729. (Pubitemid 39208405)
42. Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut. 2010;59:752-759.
43. Bilyard KG, Joseph EC, Metcalf R. Mesalazine: an overview of key preclinical studies. Scand J Gastroenterol Suppl. 1990;172:52-55. (Pubitemid 20206668)
44. Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology. 1998;114:23-28. (Pubitemid 28020950)
45. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007;133:1106-1112. (Pubitemid 47494456)
46. Marteau P, Tennenbaum R, Elefant E, Lemann M, Cosnes J. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther. 1998;12:1101-1108. (Pubitemid 28508723)
47. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25:271-275.
48. Hernandez-Diaz S, Mitchell AA, Kclley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect. 2009;117:185-189.
49. Jansen G, van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum. 2004;50:2130-2139. (Pubitemid 38924390)
50. Riley SA, Lecarpentier J, Mani V, Goodman MJ, Mandal BK, Turnberg LA. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. Gut. 1987;28:1008-1012.
51. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
52. Kane SV, Flicker M, Katz-Nelson F. Tobacco use is associated with accelerated clinical recurrence of Crohn's disease after surgically induced remission. J Clin Gastroenterol. 2005;39:32-35. (Pubitemid 40041340)
53. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656.
54. Hrobjartsson A, Gotzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2010;20:CD003974.